Extracorporeal Photopheresis of Patients With Crohn's Disease Using 5-aminolevulinic Acid

Crohn Disease Clinical Trial

Official title: Extracorporeal Photopheresis of Patients With Crohn's Disease Using 5-aminolevulinic Acid

Status Completed

Clinical Trial Summary

In the clinical trial the investigators will assess efficacy, safety and tolerability after single and multiple doses of 3 millimolar 5 aminolevulinic acid (Gliolan®) in combination with blue-light (405 nanometer) photopheresis in patients with active crohns disease. The study is a proof-of-concept pilot with up to 10 included patients where every patient will get active treatment. The use of 5-aminolevulinic acid in combination with blue-light photopheresis is a first-in-human trial. Primary endpoints include clinical response and adverse events (safety). Secondary endpoints include endoscopic improvement, quality of life questionnaires, faecal calprotectin, C-reactive protein and mechanisms of action (differences in t-cells and other cells before and after treatment). All patients will get treatment every 2 weeks for 10 weeks (6 treatments-induction) with evaluation at week 13. If any effect on week 13 eligible for study extension with treatment every 4 weeks for up to 12 months for the first 5 patients. The latter 5 patients will be referred to standard of care on the week 13 visit. Through the study the investigators will see if this kind of photopheresis is safe and can be an option for a larger randomized-controlled-trial. In addition the investigators will see if photopheresis as an option can be further developed for other diseases as well (ie other T-cell mediated diseases or patients already receiving photopheresis as a treatment).

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Crohn Disease

• NCT number: NCT04164849
• Study type: Interventional
• Source: University Hospital, Akershus
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: November 22, 2019
• Completion date: October 31, 2023